Phaseline

Companies › Elpida Therapeutics SPC

Elpida Therapeutics SPC: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Neurology; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MELPIDA
Recombinant adeno-associated virus serotype 9 (AAV9) encoding codon-optimized human AP4M1
AP4M1Phase 3Hereditary Spastic Paraplegia Type 50; Spasticity, Muscle; Spastic Paraplegia Type 50Oct 2028
ELP-02
AAV9-based gene therapy expressing FIG4
FIG4Phase 1Charcot-Marie-Tooth Disease Type 4JDec 2032

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06069687MELPIDAPhase 1Spastic Paraplegia Type 50NeurologyMar 2027
NCT05518188MELPIDAPhase 1Spasticity, MuscleNeurologyOct 2028
NCT06692712MELPIDAPhase 3Hereditary Spastic Paraplegia Type 50NeurologyFeb 2032
NCT07447557ELP-02Phase 1Charcot-Marie-Tooth Disease Type 4JNeurologyDec 2032

Targets

AP4M1 (1) FIG4 (1)

Companies with the same targets

–

Companies built like this

Alasht Pharmed MED Institute Sound Wave Innovation Dyne Therapeutics Navamedic

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.